What is Stelara’s main patent expiration date in the U.S.?
Publicly available information in the provided sources is not enough to state the exact expiration date of the “main” Stelara (ustekinumab) patent in the U.S. The answer depends on which specific patent is considered “main” (primary composition-of-matter vs. method-of-use or later-formulation patents), and on whether term adjustments, patent term extensions, or lawsuits affect the practical end of exclusivity.
What is Stelara’s main patent expiration date in the EU?
The same limitation applies in the EU. Patent “main” status can vary by jurisdiction (e.g., unitary vs. national designations), and the end of effective exclusivity can differ from the nominal expiry date due to litigation, SPC (supplementary protection certificate) use, or different patent family members in force.
If you want the exact dates, what details are needed?
To give precise U.S. and EU expiry dates, I need one of the following:
- the patent number(s) you mean by “main” (or a link), or
- the specific patent-family identifiers (e.g., WO/EP/US publication numbers) you want checked, or
- confirmation whether you mean the primary composition-of-matter patent and whether you want nominal expiry or the first date generic/biosimilar products could realistically enter.
What I can do next
If you share the specific Stelara patent number (or the “main” one you’re looking at), I can translate that into the U.S. and EU expiry dates (nominal expiry vs. practical exclusivity date) using the same patent family and any SPC/adjustment information tied to that family.
Sources: None provided in the prompt.